Multi-targeting Agents for Alzheimer's Plaque Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, such as acetylcholinesterase inhibitors and anti-amyloid monoclonal antibodies, have limited effectiveness in reducing amyloid beta plaques in the brain, and existing methods for removing Aβ plaques are either ineffective or pose adverse effects, highlighting the need for innovative approaches to target and remove these plaques effectively.
Innovation Solution
Development of multi-targeting agents that combine an amyloid beta plaque targeting agent with a second targeting agent, such as a P-glycoprotein substrate or nicotinic α4β2 receptor ligand, to facilitate the removal of Aβ plaques from the brain and surrounding vasculature, utilizing covalent bonds or linkers for enhanced binding and efflux mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If acetylcholinesterase inhibitors and anti-amyloid monoclonal antibodies are used, then symptoms of memory loss and confusion are lessened, but effectiveness in reducing amyloid beta plaques is limited
Solution Approach 1:
The patent combines an Aβ plaque targeting agent with a P-glycoprotein substrate or nicotinic α4β2 receptor ligand into a single multi-targeting agent. This merging allows the compound to simultaneously bind to Aβ plaques and interact with efflux transporters or receptors to facilitate plaque removal, thereby improving effectiveness in reducing amyloid beta plaques while maintaining symptom relief benefits
Solution Approach 2:
The multi-targeting agent is designed to perform multiple functions: (1) targeting Aβ plaques through high binding affinity, (2) facilitating plaque removal via P-glycoprotein efflux mechanisms, and (3) modulating nicotinic α4β2 receptors to enhance cognitive function. This multi-functionality resolves the contradiction by achieving both effective plaque reduction and symptom relief through a single agent
2Reliability
If existing methods for removing Aβ plaques are used, then plaque removal is attempted, but the methods are either ineffective or pose adverse effects
Solution Approach 1:
The patent uses P-glycoprotein as an intermediary mechanism to facilitate Aβ plaque removal. The multi-targeting agent is designed to be recognized by P-gp efflux transporters, which actively transport the agent-bound Aβ complexes out of brain tissue into surrounding vasculature for clearance. This intermediary mechanism provides effective plaque removal while avoiding direct toxic effects on brain tissue
Solution Approach 2:
The patent modifies the chemical parameters of existing Aβ targeting agents by linking them to P-glycoprotein substrates or nicotinic receptor ligands. This parameter change transforms the agents from simple binders into active removal facilitators that exploit physiological efflux mechanisms, achieving effective plaque clearance without the adverse effects associated with more aggressive removal methods
3Reliability
If multi-targeting agents are developed combining Aβ plaque targeting with P-glycoprotein substrate or nicotinic receptor ligand, then affinity for Aβ plaques and brain retention are improved, but device complexity increases
Solution Approach 1:
The patent creates composite molecular structures by covalently linking an Aβ plaque targeting agent with either a P-glycoprotein substrate or a nicotinic α4β2 receptor ligand. This composite approach combines the high Aβ binding affinity of the targeting agent with the efflux facilitation or receptor modulation properties of the second component, achieving improved brain retention and plaque affinity while managing molecular complexity through rational drug design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multi-targeting agents demonstrate significant affinity for Aβ plaques and improved brain retention, potentially leading to effective clearance of Aβ plaques, thereby addressing the limitations of existing treatments and enhancing cognitive function in Alzheimer's disease patients.
Implementation Method 1
the Aβ plaque targeting agent is linked directly to the Aβ plaque targeting removal agent via a covalent bond or linked indirectly to the Aβ plaque targeting removal agent via the use of a covalently attached linker
Data Source
AI summary
The disclosure provides for multi-targeting agents that assist in the targeted removal of amyloid beta plaques from the brain and surrounding vasculature of subjects with Alzheimer's disease, and methods of treatment thereof.